Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell ...

Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of ...

Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of ...

A new nanoscale scanning technique developed at Imperial College London could lead to better-designed beta-blockers to slow the development of heart failure, researchers believe. A new nanoscale ...

Please provide your email address to receive an email when new articles are posted on . Children recently diagnosed with type 1 diabetes had a higher C-peptide level at 78 weeks with teplizumab vs.

REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A single 14-day course of the monoclonal ...

-- Protein expression in muscle was sustained for two years following treatment in the low dose cohort, with mean beta-sarcoglycan expression of 54% at 24 months, compared to 36% at Day 60, as ...